Daiichi Sankyo Buys Out China Shell Company To Breathe New Life Into Ranbaxy
This article was originally published in PharmAsia News
While Daiichi Sankyo has relied on Ranbaxy's sales presence in other emerging markets, it has decided to buy a stake in China to give Ranbaxy's portfolio a second chance in the country.
You may also be interested in...
MUMBAI - For large Indian drug companies, China has been a traditional and, to an extent, a dreaded rival in the business of pharmaceutical raw materials. Gargantuan Chinese factories that cropped up in the eighties almost killed scores of Indian bulk drug manufacturing units as every pricing strategy the Indian outfits could conceive of failed to beat the quotations offered by Chinese manufacturers to global brand name companies
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.